- Home
- MYGN vs UTL Comparison
MYGN vs UTL Comparison
Compare MYGN & UTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- UTL
- Stock Information
- Founded
- MYGN 1991
- UTL 1984
- Country
- MYGN United States
- UTL United States
- Employees
- MYGN N/A
- UTL N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- UTL Power Generation
- Sector
- MYGN Health Care
- UTL Utilities
- Exchange
- MYGN Nasdaq
- UTL Nasdaq
- Market Cap
- MYGN 744.7M
- UTL 879.5M
- IPO Year
- MYGN 1995
- UTL N/A
- Fundamental
- Price
- MYGN $4.92
- UTL $51.81
- Analyst Decision
- MYGN Hold
- UTL Hold
- Analyst Count
- MYGN 15
- UTL 1
- Target Price
- MYGN $15.14
- UTL $55.00
- AVG Volume (30 Days)
- MYGN 2.1M
- UTL 62.9K
- Earning Date
- MYGN 08-05-2025
- UTL 08-05-2025
- Dividend Yield
- MYGN N/A
- UTL 3.48%
- EPS Growth
- MYGN N/A
- UTL N/A
- EPS
- MYGN N/A
- UTL 2.93
- Revenue
- MYGN $831,300,000.00
- UTL $486,900,000.00
- Revenue This Year
- MYGN N/A
- UTL $16.37
- Revenue Next Year
- MYGN $6.68
- UTL $5.20
- P/E Ratio
- MYGN N/A
- UTL $17.66
- Revenue Growth
- MYGN 7.38
- UTL N/A
- 52 Week Low
- MYGN $3.81
- UTL $49.43
- 52 Week High
- MYGN $29.30
- UTL $63.52
- Technical
- Relative Strength Index (RSI)
- MYGN 46.03
- UTL 34.56
- Support Level
- MYGN $4.78
- UTL $51.10
- Resistance Level
- MYGN $5.29
- UTL $53.91
- Average True Range (ATR)
- MYGN 0.32
- UTL 1.11
- MACD
- MYGN 0.11
- UTL -0.07
- Stochastic Oscillator
- MYGN 60.98
- UTL 17.54
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About UTL UNITIL Corporation
Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. The Company has two operating and reportable segments: Utility Electric Operations and Utility Gas Operations. Majority of revenue is gained from Electric Segment.